TRIM32 promotes retinoic acid receptor α-mediated differentiation in human promyelogenous leukemic cell line HL60.

[1]  T. Ariga,et al.  TRIM32 promotes neural differentiation through retinoic acid receptor-mediated transcription , 2011, Journal of Cell Science.

[2]  Qiaojun He,et al.  Inhibition of all‐Trans‐retinoic acid‐induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells , 2011, Molecular carcinogenesis.

[3]  M. Kulesz-Martin,et al.  Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. , 2010, The Journal of investigative dermatology.

[4]  M. Kikuchi,et al.  TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. , 2009, Biochimica et biophysica acta.

[5]  Hanns Lochmüller,et al.  Intragenic deletion of TRIM32 in compound heterozygotes with sarcotubular myopathy/LGMD2H , 2009, Human mutation.

[6]  D. Soprano,et al.  HACE1: A novel repressor of RAR transcriptional activity , 2009, Journal of cellular biochemistry.

[7]  D. Blake,et al.  TRIM32 is an E3 ubiquitin ligase for dysbindin , 2009, Human molecular genetics.

[8]  Eugene Berezikov,et al.  The TRIM-NHL Protein TRIM32 Activates MicroRNAs and Prevents Self-Renewal in Mouse Neural Progenitors , 2009, Cell.

[9]  X. Jing,et al.  E3 ligase FLRF (Rnf41) regulates differentiation of hematopoietic progenitors by governing steady-state levels of cytokine and retinoic acid receptors. , 2008, Experimental hematology.

[10]  S. Fukuda,et al.  Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. , 2008, Cancer research.

[11]  S. Hatakeyama,et al.  TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. , 2008, Cancer research.

[12]  M. Henriksson,et al.  Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid. , 2008, Leukemia research.

[13]  Lucia Altucci,et al.  Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.

[14]  N. Sakuragi,et al.  Ligand-dependent transcription of estrogen receptor α is mediated by the ubiquitin ligase EFP , 2007 .

[15]  Thomas L Casavant,et al.  Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Kudryashova,et al.  Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. , 2005, Journal of molecular biology.

[17]  G. Meroni,et al.  TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligases , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[18]  S. Nisole,et al.  TRIM family proteins: retroviral restriction and antiviral defence , 2005, Nature Reviews Microbiology.

[19]  Guang-Biao Zhou,et al.  Acute promyelocytic leukemia: A model of molecular target based therapy , 2005, Hematology.

[20]  P. Chambon,et al.  Phosphorylation by p38MAPK and recruitment of SUG‐1 are required for RA‐induced RARγ degradation and transactivation , 2002, The EMBO journal.

[21]  C. Greenberg,et al.  Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. , 2002, American journal of human genetics.

[22]  I. Roninson,et al.  Retinoid-Induced Growth Arrest of Breast Carcinoma Cells Involves Co-Activation of Multiple Growth-Inhibitory Genes , 2002, Cancer biology & therapy.

[23]  P. Chambon,et al.  F9 embryocarcinoma cells: a cell autonomous model to study the functional selectivity of RARs and RXRs in retinoid signaling. , 2001, Histology and histopathology.

[24]  L. Altucci,et al.  Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL , 2001, Nature Medicine.

[25]  Alessandro Guffanti,et al.  The tripartite motif family identifies cell compartments , 2001, The EMBO journal.

[26]  P. Chambon,et al.  Dimerization with Retinoid X Receptors and Phosphorylation Modulate the Retinoic Acid-induced Degradation of Retinoic Acid Receptors α and γ through the Ubiquitin-Proteasome Pathway* , 2000, The Journal of Biological Chemistry.

[27]  Alexander Varshavsky,et al.  The ubiquitin system. , 1998, Annual review of biochemistry.

[28]  M. Koken,et al.  Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .

[29]  E. Dmitrovsky,et al.  Retinoic Acid Promotes Ubiquitination and Proteolysis of Cyclin D1 during Induced Tumor Cell Differentiation* , 1999, The Journal of Biological Chemistry.

[30]  Y. Carpentier,et al.  Cofactors in in vitro induction of apoptosis in HL60 cells by all-trans retinoic acid (ATRA). , 1998, Biochemical pharmacology.

[31]  C. Niu,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. , 1997, Blood.

[32]  James M. Roberts,et al.  Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. , 1996, Genes & development.

[33]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[34]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.